Cilnidipine

Cilnidipine

Clinical data
Trade names	Atelec (アテレック), Cilaheart, Cilacar
AHFS/Drugs.com	International Drug Names
ATC code	C08CA14 (WHO)
Identifiers
IUPAC name 3-(E)-3-Phenyl-2-propenyl 5-2-methoxyethyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
CAS Number	132203-70-4
PubChem CID	5282138
IUPHAR/BPS	7767
ChemSpider	4445338
UNII	97T5AZ1JIP
KEGG	D01173
CompTox Dashboard (EPA)	DTXSID0046309
ECHA InfoCard	100.162.338
Chemical and physical data
Formula	C27H28N2O7
Molar mass	492.528 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(OCCOC)\C2=C(\N/C(=C(/C(=O)OC\C=C\c1ccccc1)C2c3cccc([N+]([O-])=O)c3)C)C

Cilnidipine is a calcium channel blocker. Cilnidipine is approved for use in Japan, China, India, Nepal, and Korea for hypertension.

It is a calcium antagonist accompanied with L-type and N-type calcium channel blocking functions. Unlike other calcium antagonists, cilnidipine can act on the N-type calcium channel in addition to acting on the L-type calcium channel.

It was patented in 1984 and approved for medical use in 1995. Cilnidipine is currently being repurposed and developed for use in patients with Raynaud's Phenomenon and Systemic Sclerosis by Aisa Pharma, a US biopharma development company.^[1]